T h e circulating lymphocytes of 88 consecutive patients following autologous, conventional, o r T-cell depleted bone marrow transplantation w e r e serially analyzed for B-cell surface antigen expression and function. In t h e majority of patients, e x c e p t for t h o s e w h o developed chronic graftversus-host disease, t h e number of circulating CD20' B cell normalized by t h e fourth posttransplant month. T h e earliest detectable B cells normally expressed HLA-DR. CD19, surface immunoglobulin (slg), CD21, Leu-8, and lacked expression of CDIO (CALLA). In addition, t h e circulating B cells expressed CDlc, CD38. CD5. and CD23 for t h e first year following transplant, antigens t h a t a r e nor- becoming a minor B-cell subset in older children and adults who have reached full immunologic competence. Previous reports demonstrating that the return of serum immunoglobulin isotypes and IgG subclasses posttransplant follows a pattern similar to that seen in normal prompted us to determine whether humoral immune deficits following transplant might be related to the presence of immunologically naive or immature surface immunoglobulin (sIg) positive cells similar to those found in cord blood and SCID patients. To answer this question, the sIg positive cells of consecutive patients following autologous, conventional, or T-cell depleted bone marrow transplantation were serially analyzed for surface antigen expression and function, and compared with those seen during normal childhood.
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MATERIALS AND METHODS
Eighty-eight durably engrafted patients following autologous, conventional, or T-cell depleted bone marrow transplantation were included in this study. A subset (39%) of patients with less than 6 months of follow-up in a prior study reported by this group;' were included in this analysis, in which their follow-up was extended by a minimum of one year. Patients received an HLA-identical allogeneic transplant for acute lymphoblastic (ALL) or acute myelogenous leukemia (AML) in remission of
Patients and controls.
in normal adults, but highly expressed o n cord blood B cells. Similar to cord blood B cells, patient B cells isolated during t h e first year following transplant, proliferated normally to Staphylococcus aureus Cowan strain I (SAC). and produced IgM, but minimal or n o IgG w h e n stimulated with pokeweed mitogen and SAC, unlike normal adult B cells t h a t produce both. T h e similar phenotype a n d function of posttransplant and cord blood B cells, a n d their similar rate of decline in patients and normal children a d d s further evidence to support t h e hypothesis t h a t B-cell differentiation posttransplant is recapitulating normal B-cell ontogeny.
6 1990 by The American Society of Hematology. chronic phase, chronic myelogenous leukemia (CML). These patients were cytoreduced with 1500 cGy of hyperfractionated total body irradiation (TBI) followed by two days of cyclophosphamide at 60 mg/kg per dose. Twenty-nine patients (median age 12.3 years, range 3 to 37) received a conventional transplant for ALL (n = 15) or AML (n = 14). Patients received cyclosporine A and methotrexate for GVHD prophylaxis." Eleven patients did not develop acute GVHD; 9 patients developed grade I, 4 patients grade II,4 patients grade 111, and 1 patient grade IV GVHD. Chronic GVHD occurred in ten patients. Forty-four patients (median age 24.1 years, range 6 to 47) received a T-cell depleted transplant for CML (n = 21), ALL (n = 8), or AML (n = 15). The bone marrow was T-cell depleted with soybean agglutinin followed by rosetting with sheep red blood ~ells.2~ These patients did not receive any GVHD prophylaxis, and did not develop GVHD. Eight patients received an autologous transplant for neuroblastoma (median age 4.0 years, range 2-7) following cytoreduction with cis-platinum, hyperfractionated radiation to previous disease sites, BCNU, and either melphelan or thiotepa.24 The bone marrow was purged with 4-hydroxyperoxycycloph~sphamide.'~ Seven patients received an autologous transplant for AML (median age 11.5, range 3 to 29) after cytoreduction with hyperfractionated TBI (1500 cGy), etoposide (250 mg/m2/ x 3 days), and cyclophosphamide (60 mg/kg per dose x 2 days). The bone marrow was purged with 4-hydroxyperoxycyclophosphamide and VP-16.26 Normal controls consisted of cord blood samples from nine healthy neonates, and peripheral blood from nine sibling donors (age 2 to 12 years, median 4) of patients undergoing therapeutic bone-marrow transplantation, and 85 healthy hospital or laboratory personnel. These studies were performed after informed consent was obtained under protocols approved by the Human Subjects Review Committee of Memorial Hospital and the Committee on Human Rights in Research of the New York Hospital-Cornell Medical Center.
Heparinized blood was collected from patients every three to six months following bone marrow transplantation. Peripheral blood mononuclear cells (PBMC) were collected after centrifugation on Ficoll-Hypaque density gradientsz7 Monocytes were removed from samples by plastic adherence at 37OC for 1 hour.
Immunofluorescence analysis. Directly fluoresceinated (FITC) HLe-1 (CD45, common leukocyte antigen), MsIgG, Leu-16 (CD20, pan-B cell), CALLA (CDlO, pre-B cell), and phycoerythrinconjugated (PE) MsIgG, Leu-1 (CD5), Leu-4 (CD3, pan-T cell), Leu-16, Leu-17 (CD38), HLA-DR, Leu-8, Leu-19 (CD56, natural killer (NK cell) and unconjugated Leu-5 (CD2, sheep red blood cell receptor, pan-T cell and NK cell) were purchased from Becton Dickinson (Mountain View, CA). FITC-conjugated B4 (CD19, pan-B cell), B2 (CD21, B-cell subset marker), Mo2 (monocytespecific) and PE-conjugated TQ1 were obtained from Coulter Immunology (Hialeah, FL). FITC-conjugated antibody reactive with sIg and unconjugated OKTlO (CD38) were purchased from Ortho Diagnostic Systems (Raritan, NJ). M241 (CDlc) and PL13 (CD23). were generously supplied by Dr Robert K n o w l e~.~*~~~ Two-color direct immunofluorescence was performed on monocytedepleted peripheral blood lymphocytes using standard techniques." Two-color immunofluorescence utilizing direct PE-conjugated and indirect FITC-conjugated reagents required three separate antibody incubations, with two washes between incubations. Cells were treated sequentially with the mouse anti-human unconjugated antibody, followed by the FITC-conjugated goat anti-mouse reagent. The final incubation was with the directly conjugated phycoerythrin mouse anti-human monoclonal antibody. This order was utilized to prevent nonspecific binding of the FITC-conjugated goat antimouse antibody to the PE-conjugated mouse anti-human monoclonal antibody.
Immunofluorescence was performed on isolated monocytedepleted peripheral blood lymphocytes or on whole blood. The whole-blood technique consisted of the addition of appropriate amounts of undiluted conjugated antibody to 50 p L of whole blood, followed by a half-hour incubation at rmm temperature. Red cells were then lysed with a 1/10 dilution of FACS lysis solution (Becton Dickinson), followed by two washes.
Immunofluorescence samples were analyzed on an EPICS C-cell sorter (Coulter Immunology) or a FACScan (Becton Dickinson). The lymphoid populations to be analyzed were gated on using log 90 degree and forward angle scatter characteristics. The leukocytespecific monoclonal antibody HLe-1 (CD45) was used to gate out any residual red cells. Monocyte contamination was ruled out by lack of reactivity (<I%) of the gated lymphoid cells with the monocyte specific marker Mo2.
In vitro B-cell mitogen assays. 1 x lo5 monocyte-depleted peripheral blood lymphocytes were stimulated with 0.01% S t a p h y b coccus aureus Cowan strain I (SAC) (Pansorbin, Calbiochem, La Jolla, CA) or rabbit anti-human IgM (anti-p) coupled to polyacrylamide beads (4,2, or 1 pg/mL) in RPMI-1640 supplemented with 25 mmol/L hepes buffer, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, lo-' M 2-mercaptoethanol, and 10% fetal bovine serum (Hazelton, Lenexa, KS). Cultures were maintained for 72 hours at 37O in 5% humidified CO,. Cells were labeled with 1 pCi/well of tritiated thymidine (6.8 pCi/mmol/L) (New England Statistical analysis. Serial observations for cell surface markers and in vitro functional responses were recorded for each patient at 3 to 6 month intervals. To determine if results between transplant groups were the same, a non-parametric Kruskal Wallis test" was performed within each of the time intervals. As a result of using multiple significance tests, the Bonferroni inequality was im~lemented.~~ If the test in any time interval produced a P-value less than .01, then the hypothesis of no difference between the transplant groups was rejected for that time interval.
RESULTS
Serial phenotypic analyses performed on the circulating lymphocytes of 88 patients following T-cell depleted (Lectin group), conventional, or autologous bone marrow transplantation revealed that the number of CD20+ B cells rapidly increased after the third month following each of the three types of bone marrow transplantation (Fig 1) . At time points greater than three months, most patients, except those with chronic GVHD, had normal or greater than normal numbers of circulating B cells. Patients with cGVHD accounted for median: 34%. and young children (n = 9): age 2 to 12 years, median 4.0 10% to 30%. median 22%. 85% of the recipients of conventional transplants who had less-than-normal numbers of circulating B cells after the third transplant month. Patients with cGVHD had significantly fewer numbers of CD20+ cells from 3 to 9 months post transplant (P < .0002 at 3 to 6 months, P < .015,6 to 9 months). By 9 months post BMT, these differences were no longer significant (P > .14).
LOG RED FLUORESCENCE
For The circulating CD20+ cells normally expressed HLA-DR, sig, CD19 (B4), CD21 (B2), TQ1, Leu-8, and lacked expression of CDlO (CALLA) at all time points post transplant. This is demonstrated in Fig 2, in a representative analysis of the CD20+ cells of a patient 3.5 months following a conventional bone-marrow transplant. Except for rare patients ( t 5 % ) , no differences could be demonstrated between the expression of these eight antigens on the earliest detectable B cells and those cells analyzed a t later time points posttransplant (data not shown). In contrast to the results observed with these B-cell markers, the percentage (and absolute number) of CD5+ B cells was above normal levels in the majority of patients during the first nine months post transplant (Fig 3) , as shown in the two-color histograms performed on a patient 6 months following a conventional transplant (Fig 4) . These profiles demonstrate that CD5 antigen density on the surface of B cells is low in contrast with the high-antigen density of CD5 on the CD3+ T cells. After the first nine months posttransplant, there was a gradual decline to the more normal levels that were detected by the second posttransplant year (Fig 3) . There were no significant differences among the three transplant groups in this pattern of CD5 B-cell expression (P > .01).
The expression of C D l c (M241), CD38 (OKTlO), and CD23 (PL13) on circulating B cells posttransplant is shown in Fig 5. Whereas the majority of circulating B cells during the first 6 to 12 months post BMT are CDlc, CD38, and CD23 positive, the expression of these antigens markedly decreases during the second year posttransplant. No appreciable differences in the expression of these antigens among the three transplant groups were appreciated. As shown in Fig 5, these antigens are also strongly expressed on the circulating B cells of healthy neonates, but expression decreases with age, such that the B cells of older children (>2 years) and healthy adults are predominantly CDlc, CD38, and CD23 negative. The decline of CDlc, CD38, and CD23 expression, normally observed in the posttransplant period, is illustrated in the histograms in Fig 6, which represent analyses performed on the circulating lymphocytes of a patient 4 and 18 months after a T-cell depleted transplant, as well as parallel studies of B cells of a healthy neonate and adult (Fig 6B) .
In vitro responses to the T-cell independent mitogen SAC demonstrated that co-incident with the return of circulating B cells 3 to 6 months posttransplant, the SAC response normalized in the majority of patients (Fig 7) . There were no significant differences among the transplant groups (P > .01). Five of 8 patients who had an abnormal SAC response more than three months after a conventional transplant had cGVHD, and generally had lower-than-normal numbers of circulating B cells. Once the SAC response normalized, the anti-p response was also within the normal range in 73%, 86%, and 93% of samples following an autologous, conventional, or T-cell depleted transplant, respectively.
Analysis of in vitro immunoglobulin production, utilizing a synergistic combination of PWM and SAC, demonstrated in the second year after transplant was consistently observed in our patients. These results were based on studies of individual patients serially tested on multiple occasions and were seen whether the staining was performed on whole blood or on purified monocyte-depleted lymphocytes.
Recently, it was reported that B cells isolated from individuals studied during the first 7 months posttransplant (n = 7) expressed increased levels of CD23 in association with decreased Leu-8 and CD19 expression, unlike normal controls and patients tested greater than ten months posttransplant.' Although normal B cells demonstrate an increase in CD23 expression and loss of Leu-8 expression with a c t i~a t i o n~.~' .~~ the early B cells of these patients showed abnormalities of B-cell activation, proliferation, and differentiation, even in the presence of low molecular weight B-cell growth factor, the proposed ligand of CD23.4' It was concluded that a dichotomy exists between B-cell phenotype and function in the early posttransplant period. Although our that IgM production normalizes in conjunction with the return of circulating B cells to the periphery, after the third month posttransplant. However, under identical culture conditions, significant IgG production did not occur in most patients until the second year post BMT (Fig 8) , when the predominant B-cell population expressed more normal levels of CD5, CDlc, CD38, and CD23, as previously illustrated. No significant differences were seen among the transplant groups (P > .01). These differences in in vitro immunoglobulin production are similar to those seen when cord blood B cells are compared to those of normal adults (Fig 8) , as illustrated in the left-hand portion of each figure. Our studies of the functional capabilities of patient B cells during the first year posttransplant demonstrate normal responsiveness to SAC, normal IgM production, and markedly impaired IgG secretion in most patients, similar to that seen when cord blood B cells are analyzed. Apart from patients with cGVHD, no significant differences were seen among the three transplant groups. Similar to other studies performed on patients receiving conventional or chemotherapy-purged autologous marrow, poor B-cell function was consistently demonstrated during the first three months posttransplant, when the numbers of circulating B cells are low. In general, most in vitro B-cell functions normalize by 1 to 3 years posttransplant, except in those patients who develop
The early normalization of our patients SAC and anti-M response, and in vitro IgM production differs from some studies in which abnormal proliferation and differentiation was demonstrated when T-cell deFor personal use only. on November 10, 2017. by guest www.bloodjournal.org From pleted, B-cell enriched populations were
In these reports although T cells were removed, significant percentages of monocytes remained (50% to 70%), which may suppress in vitro patient B-cell responses and account for these observed differences.s9@'
Although the ability to secrete IgM in response to a variety of polyclonal B-cell activators is present at birth, the ability to produce IgG is gradually attained between birth and two years of age.6'S6* In our transplant patients, the in vitro ability 
